Tag: Pharma
-
/C O R R E C T I O N — Piramal Pharma Solutions/
In the news release, Piramal Pharma Solutions Launches New Microbiology Laboratory at Its Lexington, KY Sterile Injectable Facility, issued 06-Oct-2026 by Piramal Pharma Solutions over PR Newswire, we are advised by the company that changes have been made to the caption accompanying the first image….
-
Piramal Pharma Solutions Launches New Microbiology Laboratory at Its Lexington, KY Sterile Injectable Facility
The new microbiology laboratory and sterility testing suite are designed for GMP drug product applications.This addition is part of the broader Lexington expansion and includes a dedicated sterility testing isolator, three new biosafety cabinets, and enhanced laboratory capacity.The remainder of the…
-
Piramal Pharma Solutions and NP2 to Complete Cyclophosphamide Development Phase Next Month
Piramal and NP2 are set to complete the drug development phase of the generic cancer drug cyclophosphamide this October. The development and manufacturing activities are being conducted at Piramal’s dedicated sterile injectable facility in Lexington, Kentucky. This partnership addresses ongoing cycl…
-
Ontario Contributes $1.7 Million Investment to Advance Life Sciences Innovation at Piramal Pharma's Aurora Facility
Piramal Pharma Solutions is investing over $5.3 million in its Aurora drug substance facility to upgrade site infrastructure.With its investment through the Life Sciences Scale-Up Fund, the Ontario government is supporting healthcare innovation and reinforcing its province’s leadership position in t…
-
Piramal Pharma Solutions Advances Sustainability Efforts with Solar Power Plant Addition at Morpeth, UK Site
Piramal Pharma Solutions is installing a ground-mounted solar power plant (4.3 MWp) at its integrated drug substance and drug product site in Morpeth, UK. The new plant will provide renewable energy directly to the site through a behind-the-meter setup, supporting Piramal’s commitment to reduce Scop…
-
Laminar Pharma Announces "Last Patient, Last Visit" in LAM561 Phase 2b/3 Trial for Newly Diagnosed Glioblastoma Patients
PALMA DE MALLORCA, Spain, July 24, 2026 /PRNewswire/ — Laminar Pharma, a leader in the development of innovative therapies based on a novel membrane lipid therapy approach, today announced that the last patient has completed their last visit (LPLV) in the company’s Phase 2b/3 clinical trial of its …
-
Piramal Pharma Solutions Highlights Strong Performance Across More Than 200 Customer Audits
Piramal Pharma Solutions completed more than 200 customer audits and received over 70 approvals from regulatory agencies across its global network over the past year, with strong overall outcomes.This milestone reflects the Company’s long-range quality strategy focused on sustained compliance, conti…
Latest News
About the Author
Publicize Your Brand
Through our news networks, we raise millions of users’ awareness. We are among the world’s most reputable news networks.
